Cannabidiol (CBD), the phytocannabinoid discovered in 1940, is seemingly everywhere these days. In states where it is legal, it is in drinks, pet products and ointments. FDA frowns on CBD’s ubiquity. Over the years, the agency has warned several companies for selling unapproved CBD-based products.
The small molecule drug discovery company Innovation1 Biotech (OTCQB:IVBT) is developing a novel CBD-inspired drug to treat a rare form of epilepsy.
Innovation1’s approach aims to build on the success of Epidiolex (CBD). Originally developed by GW Pharmaceuticals, Epidiolex became and FDA-approved drug in 2018 to treat two rare and severe forms of pediatric epilepsy when used with the benzodiazepine clobazam. In 2020, Epidiolex won an indication for seizures associated with tuberous sclerosis complex.
Although scores of companies are working to develop drugs based on Schedule 1 substances, Epidiolex is a rare success story. In 2021, Epidiolex had …